The 5th Circuit’s ruling on mifepristone “is bad for health care access, and it’s also bad for innovation,” writes Grace E.
Supreme Court restores access to abortion pill mifepristone through telehealth, mail, and pharmacies
The Supreme Court on Monday restored broad access to the abortion pill mifepristone, blocking a ruling that had threatened to ...
A rodent-borne illness is suspected of causing an outbreak aboard a cruise ship that has killed three people and sickened ...
Two drugmakers asked the U.S. Supreme Court to restore mail-order access to the abortion pill mifepristone, after an appeals ...
A research letter published on Monday in JAMA Pediatrics argues that paternal mortality deserve more attention ...
It's tough to write nuanced headlines, but a new study on AI in emergency rooms is getting way overhyped.
A second shot at gene therapy for Huntington's, China's tightening grip on pharma supply chains, and more Readout biotech ...
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for ...
A federal appeals court on Friday ruled that mifepristone, known as the abortion pill, can be distributed only in person and ...
Labs are seeing fewer applications from international students and researchers, and some doctoral students are considering ...
"Blue zones" as a concept have strayed far and wide from their humble roots, write Shelley Wood and Eric Topol.
China is now a peer competitor in drug innovation — and it intends to stay that way on its own terms, writes Dennis Kwok.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results